Lepu Biopharma Shareholders Approve RSU Scheme and Share Mandate at 2025 EGM

Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has shared an announcement.

Lepu Biopharma Co., Ltd. reported that its 2025 second extraordinary general meeting, held in Beijing on December 18, 2025, was duly convened in compliance with PRC laws and the company’s Articles of Association, with all resolutions passed as valid by shareholder poll. Shareholders overwhelmingly approved the adoption of the company’s Restricted Share Unit (RSU) Scheme, the establishment of a mandate limit allowing up to 5% of the company’s issued share capital (excluding any treasury shares) to be used for new share awards under the RSU Scheme and other share schemes, and authorized directors to amend the Articles of Association to reflect any resulting changes in share capital and to handle all related regulatory procedures, reinforcing the company’s ability to implement equity incentives and potentially enhance long‑term alignment between management, employees and investors.

The most recent analyst rating on (HK:2157) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.

More about Lepu Biopharma Co. Ltd. Class H

Lepu Biopharma Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed on the Hong Kong Stock Exchange. The company operates in the biopharma industry, focusing on the development and commercialization of innovative therapies, and uses equity-based incentive tools such as restricted share unit (RSU) schemes to attract and retain talent in a competitive healthcare and life sciences market.

Average Trading Volume: 11,497,463

Technical Sentiment Signal: Sell

Current Market Cap: HK$9.81B

Learn more about 2157 stock on TipRanks’ Stock Analysis page.